We could also expect to gain potential insight into how Merck will defend these cases in the future.
Trenton, N.J. (PRWEB) April 09, 2013
A new Fosamax leg injury trial begins in Trenton, N.J., on April 9.* The plaintiff fell in her driveway and broke her femur. She alleges that seven years of Fosamax use put her thigh at risk for the fracture. The Rottenstein Law Group, which represents clients in Fosamax lawsuits, has been monitoring Fosamax trials via numerous sources and provides updates at http://www.fosamaxlawsuitscenter.com.
According to Bloomberg, Bernadette Glynn of Cohoes, N.Y., suffered the fall in 2009 and filed her lawsuit against Fosamax manufacturer Merck in late 2011 (Glynn v. Merck & Co., 3:11-cv-05304, U.S. District Court for the District of New Jersey).
“This could be an important trial for those who believe that their Fosamax use has increased their risk of femur fracture,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “We could also expect to gain potential insight into how Merck will defend these cases in the future.”
Fosamax, its generic equivalent and other similar bisphosphonate drugs are prescribed to treat osteoporosis. In 2010, according to Bloomberg, a study published in the Journal of Bone and Mineral Research found that the drug, approved in 1995, could be linked to an increase in femur fractures. About 94 percent of the 310 patients studied who had an uncommon thigh fracture were also taking a Fosamax-type drug, many for more than five years, according to the research cited in Bloomberg.
This new trial comes about three weeks after the first femur-fracture side effects Fosamax trial (Su v. Merck & Co., ATL-L-0789-11-MT, Superior Court of New Jersey (Atlantic City)) ended abruptly in a mistrial following the plaintiff’s suffering a heart attack.
Nationwide Fosamax lawsuits were categorized into two different federal pretrial case consolidations for efficiency purposes. Cases involving alleged femur fractures are handled in the U.S. District Court for the District of New Jersey (MDL-2243). Lawsuits related to Fosamax’s alleged jaw death side effects are being handled in the U.S. District Court for the Southern District of New York (MDL-1789).
The Rottenstein Law Group represents clients who believe they have been harmed by Fosamax and encourages people to visit the firm’s Fosamax lawsuits site for more news on trials and comprehensive information about the drug.
About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com